2025 Cancer Research Institute (CRI) Clinical Innovator


Descriptions

Opportunity type:

Grant

Sponsor:

Cancer Research Institute (CRI); 207749; Active

Award amount and duration:

Up to USD $1 million for each clinical trial

Currency:

USD

Eligibility

Type:
Faculty

Candidates must be the Principal Investigator (PI) of the proposed study. CRI has no citizenship restrictions, and research supported by the award may be conducted at medical schools or research centers in the United States or abroad. Please note that CRI does not support research at for-profit institutions.

Summary

The Clinical Innovator provides funding for clinician-scientists aiming to launch innovative phase I/II or phase II clinical studies using novel immunotherapies. In addition to the merits of the clinical and scientific rationale, studies will be selected based on their novelty, feasibility, and clinical impact. Competitive applications will have a strong focus on yielding mechanistic insights into clinical response and potentials for biomarker discovery and/or validation. CRI will coordinate efforts on selected trials by advising on the following areas: standardizing sample collection, correlative assays, analysis, and data sharing, including, if applicable, deposition of immunogenomic data into the CRI iATLAS platform. 

The Clinical Innovator will provide up to USD $1 million for each clinical trial it supports. The funds may be used for salary, supplies, patient costs, correlative assays, and data analyses. Payment will be structured into milestones to ensure that studies will advance and be brought to completion. 

The deadline to submit an Initial Protocol Concept is December 1. Candidates will be notified by late February if they are invited to submit a full proposal, including protocol. Invited applications are due May 1. If these deadlines fall on the weekend, proposals will be accepted until the close of business that following Monday.


Deadlines

Application deadlines

RSO detailed review deadline

Date:
November 13, 2024 - 12:00 PM

RSO final internal review deadline

Date:
November 27, 2024 - 12:00 PM

Program application deadline

Date:
December 1, 2024 - 9:59 PM

Approvals

NOTE: Consult your Faculty Associate Dean (Research) (ADR) regarding Faculty-specific deadlines and submission processes.

Principal Investigators: Complete a Research Management System (RMS) record, including a copy of your complete application, and submit this for approvals in RMS.

Postdocs, students, and trainees: For fellowships and externally-sponsored research training awards or opportunities, you must complete the Research Funding Application Approval (RFAA) Trainee PDF form, and submit it, along with a complete copy of the application, to Research Services at rsotrainee@ucalgary.ca. Trainees should not use RMS at this time.

Approvals: The University of Calgary requires that all funding applications be approved prior to submission. Approval requires signatures via either RMS or the RFAA Trainee form, in the following order:

  • Principal Investigator
  • Department Head
  • Faculty ADR/Dean
  • Research Services (on behalf of the Vice-President Research)

Read the Meaning of Grant Signatures policy to understand what your approval means. Please see the agency guidelines for details about which signatures are required on your application, as it may differ from internal requirements.

Late submissions: Late submissions will only be accepted in cases of medical or family emergencies, or other exceptional circumstances. If you submit your RMS record to Research Services after the internal deadline has passed, you must secure additional approvals. Please read: Late Applications Process.


Additional Information

An initial Protocol Concept must be submitted electronically using the CRI online submission portal. For more information on the application process, please visit the CRI website.

Application Resources:

Invention Disclosure Form

Annual Invention Update Form

Standard Revenue Sharing Agreement

Terms and Conditions


Contact Details


Keywords

Cancer Research Institute (CRI) Clinical Innovator
Innovative immunotherapy clinical trials
Phase I/II or phase II clinical studies
Biomarker discovery
Principal Investigator (PI)